KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $749.0 million.

  • Amgen's Change in Accured Expenses rose 288.46% to $749.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $499.0 million, marking a year-over-year increase of 44239.13%. This contributed to the annual value of $499.0 million for FY2025, which is 44239.13% up from last year.
  • Per Amgen's latest filing, its Change in Accured Expenses stood at $749.0 million for Q4 2025, which was up 288.46% from -$180.0 million recorded in Q3 2025.
  • Over the past 5 years, Amgen's Change in Accured Expenses peaked at $1.1 billion during Q4 2023, and registered a low of -$1.1 billion during Q1 2024.
  • Its 5-year average for Change in Accured Expenses is $65.7 million, with a median of -$40.5 million in 2021.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 48750.0% in 2021, then skyrocketed by 32323.23% in 2022.
  • Quarter analysis of 5 years shows Amgen's Change in Accured Expenses stood at -$267.0 million in 2021, then tumbled by 141.57% to -$645.0 million in 2022, then surged by 271.01% to $1.1 billion in 2023, then crashed by 34.0% to $728.0 million in 2024, then grew by 2.88% to $749.0 million in 2025.
  • Its Change in Accured Expenses was $749.0 million in Q4 2025, compared to -$180.0 million in Q3 2025 and $804.0 million in Q2 2025.